SOURCE: Shinesrooms.com

Shinesrooms.com

November 02, 2011 08:15 ET

Equity Research on Elan Corp. plc and Hospira Inc. - Fortunes Change Quickly in Drug Delivery

NEW YORK, NY--(Marketwire - Nov 2, 2011) - www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Delivery industry and are offering free analytical research on Elan Corp. plc (NYSE: ELN) and Hospira Inc. (NYSE: HSP). Register with us today at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index.com to have free access to these research reports.

While many companies in the Drug Delivery industry have performed strongly of late, some companies have been negatively affected by internal issues. Companies in the industry like Irish biotech firm Elan Corporation plc. have made significant gains this year by increasing their sales of effective drugs and controlling operating expenses. Elan has seen dramatic sales increases for its multiple sclerosis medication Tysabri. Elan Corp. plc report is accessible for free by registering today at http://www.shinesrooms.com/ElanCorpplc021111.pdf.

www.shinesrooms.com is the Ultimate Trading Environment for investors. If you are considering owning Elan Corp. plc and Hospira Inc. then you should sign up for a free membership and our complimentary reports today at www.shinesrooms.com. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Investors in the Drug Delivery industry should be aware that internal manufacturing problems can change a company's fortunes quickly. Such may be the case with Hospira Inc. which has lost a large amount of its value over the last few months. Get your free reports on Elan Corp. plc and Hospira Inc. at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

Hospira has had to deal with increased costs for quality improvement after the FDA announced that Hospira did not comply with regulatory standards. These expensive manufacturing problems can impair a company's ability not only to produce current drugs, but also to introduce new pharmaceuticals and to find financing for continued research and development. Hospira Inc. report is accessible for free by registering today at http://www.shinesrooms.com/HospiraInc021111.pdf.

The two Drug Delivery stocks research reports are available for free by signing up now on www.shinesrooms.com.

About Shinesrooms.com
Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

Contact Information